Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide PK in Severe Renal Impairment
NCT06643377Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours, Maximum Plasma Concentration at Day 28 and 5 more. Started Nov 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06643377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643377.